ストックスクリーナーアプリを入手
1.87
6.97%
-0.14
Skye Bioscience Inc (SKYE) 最新ニュース
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Consensus PT from Analysts - Defense World
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $16.60 - Defense World
Skye Bioscience Awards 100,000 Share Options at $1.82 with 4-Year Vesting Terms - Stock Titan
Skye Bioscience (SKYE) Reveals Key Findings on CB1 Inhibitors an - GuruFocus
Skye Bioscience Clinical Model Demonstrating Necessity of - GlobeNewswire
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by Barclays PLC - Defense World
Barclays PLC Has $198,000 Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (SKYE) Receives Adjusted Price Target from Oppen - GuruFocus
Oppenheimer cuts Skye Bioscience price target to $17 By Investing.com - Investing.com South Africa
Oppenheimer cuts Skye Bioscience price target to $17 - Investing.com
Braidwell LP Invests $2.34 Million in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire
Earnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D Expansion - Investing.com Nigeria
Skye Bioscience, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SKYE) - Seeking Alpha
Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Pro - GuruFocus
Schonfeld Strategic Advisors LLC Purchases 463,644 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and Financial Stability Amid Regulatory Challenges - GuruFocus
Skye Bioscience Q1 2025: Progress in Obesity Treatment - TipRanks
SKYE Advances Nimacimab as Promising Obesity Treatment | SKYE Stock News - GuruFocus
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity - GlobeNewswire
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Holdings Increased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Has $1.15 Million Stake in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience to Participate in May Investment and Medical Conferences - The Manila Times
Clinical-Stage Biotech Skye Sets Triple Conference Schedule: Key Obesity Drug Updates Coming in May - Stock Titan
Skye Bioscience (SKYE) Grants Stock Options to New Employee | SK - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Skye Bioscience Board Approves 19,000 Share Options Grant Under 2024 Inducement Plan - Stock Titan
Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan - Nasdaq
Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com
SIMPLY BETTER BRANDS ANNOUNCES RESULTS FOR FISCAL 2024, HIGHLIGHTING 77% INCREASE IN TRUBAR™ REVENUE, AND CORPORATE NAME CHANGE TO TRUBAR INC. - The Globe and Mail
William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat
(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com
SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):